UPDATED Nov. 18, 2014, with a clarification from JenaValve.

JenaValve Technology yesterday reported adding nearly $17.3 million to a Series C funding round, bring the total raise to nearly $79.8 million.

Last year the Wilmington, Del.- and Munich-based medical device company said it pulled in $62.5 million in the round. Although a Nov. 13 regulatory filing reports a nearly $11 million addition, a JenaValve spokeswoman told MassDevice.com that the company added $17.25 million to the Series C round, but declined to elaborate.

At the time JenaValve said it planned to use the proceeds to expand its footprint in Europe and enter the transcatheter aortic heart implant market in the U.S. and China. The updated filing lists 15 unnamed investors as participants in the round.

JenaValve said then that it planned to use the cash to fund clinical trials for its transfemoral TAVI device and expand its commercial base (a transapical TAVI model is already on the market in Europe). The company also said "it plans to pursue clinical initiatives in the U.S. as well as pursue regulatory approval for its TAVI product in China."

JenaValve is 1 of several smaller players in the TAVI space hoping to challenge market leader Edwards Lifesciences (NYSE:EW), challenger Medtronic (NYSE:MDT) and other big device makers like St. Jude Medical (NYSE:STJ) and Boston Scientific (NYSE:BSX).